The UK cannabis sector is renewing calls for additional easing of constraints on medical use of this medication, arguing that the industry is being hauled back from generating thousands of jobs as uptake remains low 3 years after legalisation.Medicinal cannabis was legalised in the UK in 2018 and can be used across the entire world to take care of health issues from epilepsy to anxiety and pain. However, a report backed by 16 industry bodies has declared the UK’s medical marijuana industry”a wreck”, detailing how since legalisation just 3 prescriptions are administered by the NHS, with roughly 6,000 in the private industry. Mike Barnes, co-founder of cannabis-focused Maple Tree Consultancy and one of the paper’s authors, said the report aimed to place”a coherent case for why it could be helpful to the UK market if we actually developed a correct medical cannabis industry”. It’s backed by an all-party parliamentary group chaired by MPs Jeff Smith and Crispin Blunt and will soon likely probably be sent to Westminster this week. The report argues that less restrictive rules on how cannabis can be grown, imported and used would create a roughly #2bn sector, dependent on a 2019 YouGov analysis that suggested 1.4m people in the UK were self-medicating using marijuana bought off the roads. It also quotes, extrapolating from US states like Florida where earnings of medical cannabis have grown quickly, that red tape has prevented the creation of thousands of tens of thousands of jobs, in areas like farming and manufacturing. The medical cannabis sector is separate from clinically tested pharmaceutical products that include cannabinoids, like the ones made by GW Pharmaceuticals, a UK industry pioneer that was this year bought by Ireland-based Jazz Pharmaceuticals at a 7.2bn bargain.Proposals in the report include that the UK government should ensure it is easier to grow cannabis for medical use and allow the extraction of this cannabinoid CBD, which currently has to be imported from overseas.Pureis, one of the first CBD brands to have been approved in the UK, has had expects to expand manufacturing in the nation quashed after the Home Office prevented it from highlighting necessary raw materials, amid concerns over the cannabinoid THC, which generates a top.CBD that doesn’t leave users feeling large can be sold across the counter, however Pureis co-founder Lady Chanelle McCoy claimed that officials were more interested to take care of all cannabis-derived products as one. “There’s nobody in the Home Office who actually understands this,” she said. Recommended The report also argues that general practitioners, rather than experts, should be allowed to prescribe cannabis. Barnes reported that this was one of the most important proposals to kickstart the industry in the UK, which he contended was tripped up as cannabis has been treated as a cultural rather than a botanical product. “You can not really do a double-blind placebo research onto a plant,” he said, arguing that health bodies in the UK, which have remained biased towards cannabis, if recognise”the vast number of real-world evidence, the case studies and observational research” on its own advantages. “It’s hangover stigma.”

0

The UK cannabis sector is renewing calls for additional easing of constraints on medical use of this medication, arguing that the industry is being hauled back from generating thousands of jobs as uptake remains low 3 years after legalisation.

Medicinal cannabis was legalised in the UK in 2018 and can be used across the entire world to take care of health issues from epilepsy to anxiety and pain.

But a report backed by 16 industry bodies has declared the UK’s medical marijuana industry”a wreck”, detailing how since legalisation just 3 prescriptions are administered by the NHS, with roughly 6,000 in the private industry. 

Mike Barnes, co-founder of cannabis-focused Maple Tree Consultancy and one of the paper’s authors, said the report aimed to place”a coherent case for why it could be helpful to the UK market if we actually developed a correct medical cannabis industry”. It’s backed by an all-party parliamentary group chaired by MPs Jeff Smith and Crispin Blunt and will soon likely probably be sent to Westminster this week.

The report argues that less restrictive rules on how cannabis can be grown, imported and used would create a roughly #2bn sector, dependent on a 2019 YouGov analysis that suggested 1.4m people in the UK were self-medicating using marijuana bought off the roads.

It also quotes, extrapolating from US states like Florida where earnings of medical cannabis have grown quickly, that red tape has prevented the creation of thousands of tens of thousands of jobs, in areas like farming and manufacturing.

The medical cannabis sector is separate from clinically tested pharmaceutical products that include cannabinoids, like the ones made by GW Pharmaceuticals, a UK industry pioneer that was this year bought by Ireland-based Jazz Pharmaceuticals at a 7.2bn bargain.

Proposals in the report include that the UK government should ensure it is easier to grow cannabis for medical use and allow the extraction of this cannabinoid CBD, which currently has to be imported from overseas.

Pureis, one of the first CBD brands to have been approved in the UK, has had expects to expand manufacturing in the nation quashed after the Home Office prevented it from highlighting necessary raw materials, amid concerns over the cannabinoid THC, which generates a top.

CBD that doesn’t leave users feeling large can be sold across the counter, however Pureis co-founder Lady Chanelle McCoy claimed that officials were more interested to take care of all cannabis-derived products as one. “There’s nobody in the Home Office who actually understands this,” she said.

The report also argues that general practitioners, rather than experts, should be allowed to prescribe cannabis. Barnes reported this was one of the most important proposals to kickstart the industry in the UK, which he contended was tripped up as cannabis has been treated as a cultural rather than a botanical product.

“You can not really do a double-blind placebo research on a plant,” he said, arguing that health bodies in the UK, which have remained biased towards cannabis, if recognise”the vast number of real-world evidence, the case studies and observational research” on its own advantages.

“It’s hangover stigma.”

Source: https://www.ft.com/content/2e5975f6-3c84-4244-8de8-16decda35f86

Leave a Reply